Ratings by BMO Capital (George Farmer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/14/2020 | Arvinas Inc. | ARVN | Maintain | Outperform (N/A) |
|
Details | ||
| 11/17/2020 | Moderna | MRNA | Downgrade | Market Perform (Outperform) |
89.39 (67.01) |
-25.04% | Details | |
| 11/6/2020 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/27/2020 | C4 Therapeutics | CCCC | New Coverage | Outperform (N/A) |
26.09 (33.32) |
27.71% | Details | |
| 10/21/2020 | Mirati Therapeutics | MRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/6/2020 | MyoKardia | MYOK | Downgrade | Market Perform (Outperform) |
139.60 (224.91) |
61.11% | Details | |
| 8/19/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/10/2020 | Pandion Therapeutics | PAND | New Coverage | Outperform (N/A) |
18.50 (60.05) |
224.59% | Details | |
| 8/5/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/3/2020 | Immunic Inc. | IMUX | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/20/2020 | Immunic Inc. | IMUX | New Coverage | Outperform (N/A) |
12.65 (14.64) |
15.73% | Details | |
| 6/30/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/8/2020 | Blueprint Medicines | BPMC | Maintain | Outperform (N/A) |
|
Details | ||
| 5/19/2020 | Moderna | MRNA | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2020 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2020 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/6/2020 | Exelixis | EXEL | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/1/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/30/2020 | Moderna | MRNA | New Coverage | Outperform (N/A) |
26.85 (67.01) |
149.57% | Details | |
| 4/20/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/20/2020 | Seattle Genetics | SGEN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2020 | MyoKardia | MYOK | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/17/2020 | Blueprint Medicines | BPMC | Upgrade | Outperform (Market Perform) |
48.11 (129.46) |
169.09% | Details | |
| 3/9/2020 | BridgeBio Pharma | BBIO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/26/2020 | Exelixis | EXEL | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/6/2020 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/28/2020 | Blueprint Medicines | BPMC | New Coverage | Market Perform (N/A) |
65.58 (48.11) |
-26.64% | Details | |
| 1/28/2020 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Market Perform (N/A) |
86.15 (59.20) |
-31.28% | Details | |
| 1/28/2020 | Mirati Therapeutics | MRTX | New Coverage | Market Perform (N/A) |
90.98 (138.50) |
52.23% | Details | |
| 1/28/2020 | Seattle Genetics | SGEN | New Coverage | Outperform (N/A) |
113.57 (228.74) |
101.41% | Details | |
| 1/3/2020 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/9/2019 | Agios Pharma | AGIO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/11/2019 | Nektar Therapeutics | NKTR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/8/2019 | Exelixis | EXEL | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/12/2019 | Agios Pharma | AGIO | New Coverage | Outperform (N/A) |
35.58 (40.55) |
13.97% | Details | |
| 9/12/2019 | Arvinas Inc. | ARVN | New Coverage | Outperform (N/A) |
23.90 (58.19) |
143.47% | Details | |
| 8/9/2019 | Nektar Therapeutics | NKTR | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2019 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 7/22/2019 | Eidos Therapeutics | EIDX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/22/2019 | BridgeBio Pharma | BBIO | New Coverage | Outperform (N/A) |
26.00 (83.08) |
219.54% | Details | |
| 5/8/2019 | Editas Medicine | EDIT | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2019 | Biogen | BIIB | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/4/2019 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/22/2019 | Exelixis | EXEL | New Coverage | Market Perform (N/A) |
21.24 (56.04) |
163.84% | Details | |
| 2/22/2019 | Nektar Therapeutics | NKTR | New Coverage | Outperform (N/A) |
43.03 (68.32) |
58.77% | Details | |
| 2/22/2019 | Biogen | BIIB | New Coverage | Market Perform (N/A) |
335.16 (209.03) |
-37.63% | Details | |
| 2/22/2019 | MyoKardia | MYOK | New Coverage | Outperform (N/A) |
43.64 (224.91) |
415.38% | Details | |
| 2/22/2019 | Protagonist Therapeutics | PTGX | New Coverage | Outperform (N/A) |
7.16 (40.58) |
466.76% | Details | |
| 2/22/2019 | Eidos Therapeutics | EIDX | New Coverage | Outperform (N/A) |
15.43 (122.21) |
692.03% | Details |
